MiNK Therapeutics, Inc.
INKTHealthcare|Biotechnology|US
$10.35
+0.30 (+2.99%)
DCF Value
$1.16
Cash / Share
$1.75
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07615010 A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure | Pneumonia | P2 | Recruiting | 90 | RCT, Double-blind | agenT-797, Placebo, Standard of Care (SOC) |
| NCT05108623 A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors | Tumor, Solid | P1 | Completed | 34 | Open-label | agenT-797, Approved ICIs |
| NCT07869368 BLinatumomab and iNKT in Relapsed B-Cell ALL | B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia) | P1 | Not Yet Recruiting | 13 | Open-label | Invariant Natural Killer T Cell Therapy |
| NCT04582201 A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS | Respiratory Distress Syndrome, Adult | P1 | Completed | 20 | Open-label | agenT-797 |
| NCT04754100 agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Multiple Myeloma | P1 | Completed | 13 | Open-label | agenT-797 |